{
  "title": "M21-1, Part V, Subpart iii, Chapter 7 - Genitourinary Disabilities",
  "url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180593/M21-1-Part-V-Subpart-iii-Chapter-7-Genitourinary-Disabilities",
  "content": "<-- Previous Section\nNext Section -->\nOverview\nIn This Chapter\nThis chapter contains the following topics:\nTopic\nTopic Name\n1\nGeneral Rating Principles for Genitourinary Disabilities\n2\nEvaluating Nephritis and Nephropathy\n3\nProstate Conditions\n4\nErectile Dysfunction (ED)\n5\nOther Genitourinary Considerations\n1\n.\nGeneral Rating Principles for Genitourinary Disabilities\nIntroduction\nThis topic contains guidance on the general principles for evaluating genitourinary dysfunction, including\nrating genitourinary disorders\nrenal dysfunction\ndetermining the chronicity of renal dysfunction\nuse of catheters and other appliances\nurinary tract infection\nrecurrent stone formation\n, and\nchanges in the rating schedule for the genitourinary system\n.\nChange Date\nNovember 15, 2021\nV.iii.7.1.a\n.\nRating Genitourinary Disorders\nThe diagnostic codes (DCs) for genitourinary disorders are at\n38 CFR 4.115b\n.  Many of those are rated by the rating formulas for dysfunction provided in\n38 CFR 4.115a\n.  The three types of genitourinary dysfunction are\nvoiding dysfunction, which provides evaluations based on\nfrequency\nleakage, and/or\nobstructed voiding\nurinary tract infections, and\nrenal dysfunction.\n38 CFR 4.115a\nprovides that diseases of the genitourinary system generally result in disabilities related to renal or voiding dysfunctions, infections, or a combination of these.\nWhere a particular DC lists more than one dysfunction under which the condition can be rated, only the predominant area of dysfunction shall be utilized for rating purposes.  Separate evaluations may not be assigned for different types of dysfunction attributable to a single condition.\nWhen different genitourinary conditions are present and each is evaluated using a different type of dysfunction, separate evaluations may be assigned.\nWhen different genitourinary conditions are present but each is evaluated using the same type of dysfunction, separate evaluations may not be assigned.\nImportant\n:\nEnsure in every case that rating decisions not pyramid or separate individual findings when those findings in their entirety constitute one disability as discussed at\nM21-1, Part V, Subpart ii, 3.D.2.b\n.\n38 CFR 4.115a\nacknowledges that since the areas of dysfunction do not cover all symptoms resulting from genitourinary diseases, specific diagnoses may include a description of symptoms assigned to that diagnosis.\nExample\n:  For pyelonephritis,\n38 CFR 4.115b, DC 7504\ndirects to rate as renal dysfunction or urinary tract infection, whichever is predominant.  If symptoms of both renal dysfunction and urinary tract infection are present and associated with pyelonephritis, assign a single evaluation based on the most disabling symptoms.\nV.iii.7.1.b\n.\nRenal Dysfunction\nRenal dysfunction is evaluated using specific, objective laboratory findings.\nGlomerular filtration rate (GFR) is widely accepted as the best overall measure of kidney function in health and disease.  There is an inverse correlation between GFR and functional impairment.\nLower GFRs correspond to greater impairment.\nIndividuals with GFRs less than 60 mL/min/1.73 m\n2\nare considered to have chronic renal disease.\nA GFR less than 15 mL/min/1.73 m\n2\nis a sign of renal failure.\nGFR, estimated GFR (eGFR), and creatinine-based approximations are acceptable for evaluation purposes, as each has been shown to be an adequate indicator of the stage of chronic kidney disease.  Elevated creatinine levels are correlated with decreasing GFR.\nProteinuria, as measured by increased urinary excretion of albumin, is an early and sensitive maker of kidney damage and is reflected by an albumin/creatinine ratio (ACR) of 30 mg/g or greater.\nV.iii.7.1.c\n.\nDetermining Chronicity of Renal Dysfunction\nAssignment of a compensable evaluation for renal dysfunction based on abnormal GFR or (other findings accepted for evaluation purposes under\n38 CFR 4.115a\n) is premised upon findings spanning over three consecutive  months.\nSatisfaction of the three-month requirement does not necessitate an individual finding in each month of a three-month period.  Rather, clinical data showing an abnormal finding with another repeated abnormal finding 3 or more months later during a 12-month period will document chronicity of the impairment and will be sufficient to satisfy this requirement unless there is evidence to the contrary.\nIt is expected that an individual with chronic renal dysfunction would be followed for treatment and clinical data would be sufficient to document chronicity of findings over the three month or longer period.\nHowever, when such clinical data is unavailable to decision makers, a one-time finding may be used to assign the corresponding disability evaluation unless there is evidence that suggests non-chronicity of the impairment.\nWhen a compensable evaluation is assigned based on a one-time finding of abnormal GFR, defer the end product and schedule an at-once examination to obtain a second GFR reading three months after the first.\nThis at-once examination is necessary to satisfy the regulatory requirement for sustained findings from a three-month period.\nReference\n:  For more information on handling improvement shown on the at-once examination, see\n38 CFR 3.105(e)\n, and\nM21-1, Part X, Subpart ii, 4.A\n.\nV.iii.7.1.d\n.\nUse of Catheters and Other Appliances\nThe term\nappliance\n, as used in the criteria for voiding dysfunction under\n38 CFR 4.115a\n, includes\nall\ntypes of catheters, as well as any other assistive device for urination.\nImportant\n:  Appliances, including catheters, may be used to treat urine leakage associated with voiding dysfunction and/or urine retention associated with obstructed voiding.  The rating activity should review the evidence carefully to determine whether the appliance is required to treat urine leakage or urine retention and evaluate on the predominant disability.\nNote\n:  For the purposes of evaluating urinary tract infection at the 30-percent rate, the use of catheters is not considered comparable to drainage by stent or nephrostomy and is inconsistent with the remainder of the criteria required for a 30-percent evaluation.  Stent and nephrostomy tube insertion are surgical procedures and require more intensive management than drainage by catheterization.\nExample 1\n:  A Veteran is\nservice-connected (\nSC) for a bladder injury.  Medical records show a catheter is required for\nurine leakage\ndue to the bladder injury.\nResult\n:  A 60-percent evaluation should be assigned for this disability based on voiding dysfunction.\nExample 2\n:  A Veteran is SC for a bladder injury. Medical records show a catheter is required for\nurine retention\ndue to the bladder injury.\nResult\n:  A 30-percent evaluation should be assigned for this disability based on obstructed voiding.\nReference\n:  For more information on ratings of the genitourinary system based on voiding dysfunction, see\n38 CFR 4.115a\n.\nV.iii.7.1.e\n.\nUrinary Tract Infection\nThe following terms are utilized in the criteria for evaluating urinary tract infection.\nSuppressive drug therapy\n, as identified in the criteria for the 0- and 10-percent disability evaluations, refers to the use of prolonged suppressive antibiotic therapy or medications for treatment of urinary tract infections.  The required duration of the therapy is identified in the rating criteria.\nContinuous intensive management\n, as identified in the criteria for the 30-percent disability evaluation, refers to the requirement for treatment beyond the use of antibiotic or other medications or hospitalizations as described in the 0- and 10-percent evaluation levels.  Examples of this level of care include but are not limited surgical management of the nephrostomy and/or stent, intravenous antibiotics, or treatment that is otherwise required for the maintenance of the nephrostomy tube or stent.\nV.iii.7.1.f\n.\nRecurrent Stone Formation\nUnder\n38 CFR 4.115b, DC 7508\n, a 30-percent disability evaluation is assigned when evidence shows recurrent stone formation requiring invasive or non-invasive procedures more than 2 times per year.\nExamples of therapeutic procedures that would satisfy these requirements include (but are not limited to)\ninvasive procedures, such as\nopen surgical lithotomy\npercutaneous nephrolithotomy (PCNL)\nretrograde intrarenal surgery (RIRS), or\nother minimally invasive endourological treatments, and\nnon-invasive procedures, such as\nshockwave lithotripsy (SWL), or\nureteroscopic fragmentation and retrieval.\nRecurrent stone formation means that there must be more than one episode of stone formation requiring treatment during a one-year period.\nV.iii.7.1.g\n.\nChanges in the Rating Schedule for the Genitourinary System\nThe rating criteria for the genitourinary system have undergone historical changes.  Recent full-scale revisions were effective on the following dates:\nNovember 14, 2021, and\nFebruary 17, 1994.\nNote\n:  These changes in the rating criteria\nare not considered liberalizing, and\nshould not be the basis for a reduction in disability rating unless medical evidence establishes that the disability has actually improved.\n2\n.\nEvaluating Nephritis and Nephropathy\nIntroduction\nThis topic contains information about general principles for rating genitourinary disabilities, including\ndefinition of nephropathy\nevaluating nephropathy\nevaluation of nephropathy and hypertension\ndefinition of nephritis\ncharacteristics of nephritis\nevaluating nephritis\nlimits on separate evaluation of nephritis and cardiovascular conditions\n, and\ndistinguishing nephritis from other types of nephropathy\n.\nChange Date\nNovember 15, 2021\nV.iii.7.2.a\n.\nDefinition:  Nephropathy\nNephropathy\nis generally defined as a condition encompassing disease or damage of the kidneys.  Nephropathy is a broader term to describe any condition that impairs renal function. Examples of nephropathy include (but are not limited to) chronic renal disease, nephrotic syndrome, and nephritis.\nV.iii.7.2.b\n.\nEvaluating Nephropathy\nFor Department of Veterans Affairs (VA) disability purposes, nephropathy is evaluated as renal dysfunction under\n38 CFR 4.115a\n.\nThe most commonly used DC for nephropathy is\n38 CFR 4.115b, DC 7541\n, “renal involvement in diabetes mellitus type I or II,” otherwise known as\ndiabetic nephropathy.\nImportant\n:  When the renal impairment is a form of nephritis,\n38 CFR 4.115\napplies as discussed in\nM21-1, Part V, Subpart iii, 7.2.f\n.\nV.iii.7.2.c\n.\nEvaluation of Nephropathy and\nHypertension\nThe provision of\n38 CFR 4.115\nthat\nstates that separate ratings are not to be assigned for disability from disease of the heart and any form of nephritis does not apply when evaluating other types of nephropathy because nephropathy is a broader diagnostic classification warranting its own evaluative approach.  Other types of nephropathy may be assigned separate evaluations for the renal impairment and heart disease and/or hypertension.\nNote\n:  Prior to the revision of\n38 CFR 4.115a\neffective on November 14, 2021, hypertension was included among the criteria for evaluation of renal dysfunction.  Consequently, under the historical criteria, separate evaluations could not be assigned for hypertension and nephropathy\nexcept\nwhen dialysis was required or when the condition was characterized by absence of the kidney as assignment of separate evaluations would have been in violation of\n38 CFR 4.14\n.\nReference\n:  For more information on the historical prohibition against separate evaluations for hypertension and nephropathy in place prior to November 14, 2021, see\n38 CFR 4.14\n, and\nthe attachment titled\nHistorical_M21-1V_iii_7_9-15-21\n.\nV.iii.7.2.d\n.\nDefinition:  Nephritis\nNephritis\nis generally defined as inflammation of the kidneys.  It includes inflammation of any renal structure such as glomeruli, tubules, or interstitial tissue. Nephritis is a form of nephropathy.\nV.iii.7.2.e\n.\nCharacteristics of Nephritis\n38 CFR 4.115\ndiscusses several medical concepts pertaining to nephritis. These concepts may be useful in determining when the duty to assist requires an examination or opinion or when medical results may need clarification.\nCharacteristics of glomerular nephritis\nUsually preceded by or associated with severe infectious disease.\nSudden onset.\nCourse marked by red blood cells, salt retention, and edema.\nMay clear up entirely or progress to a chronic condition.\nCharacteristics of nephrosclerotic nephritis\nOriginating in hypertension or arteriosclerosis.\nDevelops slowly.\nMinimum laboratory findings.\nAssociated with natural progress.\nAlbuminuria alone is not nephritis.\nDo not accept the presence of transient symptoms, such as elevated albumin and the presence of casts following febrile illness as establishing nephritis.\nV.iii.7.2.f\n.\nEvaluating Nephritis\nChronic nephritis is addressed in\n38 CFR 4.115b, DC 7502\n.  It is rated as renal dysfunction under\n38 CFR 4.115a\n.  Glomerulonephritis (\n38 CFR 4.115b, DC 7536\n) and interstitial nephritis (\n38 CFR 4.115b, DC 7537\n) also use the renal dysfunction criteria.\nNote\n:  When nephrosclerosis arises from nephritis, the evaluation criteria under\n38 CFR 4.115b, DC 7507\ndirects that\nnephrosclerosis be rated according to the predominant symptoms as\nrenal dysfunction\nhypertension, or\nheart disease, and\nif nephrosclerosis is rated under the cardiovascular schedule, the rating which would otherwise be assigned will be elevated to the next higher level.\nV.iii.7.2.g\n.\nLimits on Separate Evaluation of Nephritis and Cardiovascular Conditions\n38 CFR 4.115\nstates that separate ratings cannot be assigned for disability from disease of the heart and any form of nephritis.\nThe rationale is that there is a close interrelationship between cardiovascular disabilities and nephritis.\nExample 1\n:  The following separate evaluations are\nnot\npermitted under\n38 CFR 4.115\neven if\nthe nephritis evaluation was supportable based on definite decrease in renal function.\n7101\nHypertension\n10\n7502\nNephritis\n60\nExceptions\n:  Separate ratings for any hypertension or heart disease are permitted in the following scenarios:\nchronic renal disease has progressed to the point where regular dialysis is required, or\nif absence of a kidney is the sole renal disability, even if removal was required because of nephritis.\nExample 2\n:\nThe following separate evaluations are allowed since absence of the kidney is the sole renal disability.\n7500\nKidney – removal of one, history of glomerulonephritis\n30\n7101\nHypertension\n20\nExample 3\n:  The following separate evaluations are allowed if the 100-percent evaluation for nephritis is based on the requirement for dialysis.\n7530\nNephritis\n100\n7101\nHypertension\n10\nReference\n:  For more information on nephritis, including the different types of nephritis, see\n38 CFR 4.115\n, and\nM21-1, Part V, Subpart iii, 7.2.f\n.\nV.iii.7.2.h\n.\nDistinguishing Nephritis From Other Types of Nephropathy\nAlthough a condition may be diagnosed as nephropathy, the evidence must be carefully examined to determine if the diagnosed nephropathy can be clinically recognized as a form of nephritis that would trigger\n38 CFR 4.115\napplication.\nA nephropathy diagnosis is not dispositive for the purpose of making this distinction.\nAdditional review of the evidence beyond the given diagnosis will be necessary to determine whether the renal condition, irrespective of the diagnosis, is a form of nephritis.\nIn the following examples, the diagnosis contains the term “nephropathy” but the disability is actually a type of nephritis and must be evaluated with consideration of\n38 CFR 4.115\n.\nIgA nephropathy is generally characterized clinically as a type of primary glomerulonephritis.\n38 CFR 4.115b, DC 7537\nis the DC for interstitial nephritis, and gouty nephropathy is identified as a type of interstitial nephritis as well as other disorders of calcium metabolism.\nImportant\n:\nWhen the clinical evidence is unclear, request a medical opinion to determine whether the disability in question is a type of nephritis.\nIt is impermissible to evaluate a type of nephritis specifically identified in the rating schedule, such as gouty nephropathy, by analogy in an effort to achieve a higher disability evaluation.\n3\n.\nProstate Conditions\nIntroduction\nThis topic contains information about prostate conditions, including\nbenign prostatic hypertrophy (BPH)\ndiagnosis of prostate cancer by biopsy\nrating prostate cancer\n, and\nED and special monthly compensation (SMC) due to prostate cancer\n.\nChange Date\nJune 14, 2019\nV.iii.7.3.a\n.\nBPH\nBenign prostatic hypertrophy (BPH) is evaluated under\n38 CFR 4.115b, DC 7527\nbased on associated voiding dysfunction or urinary tract infection, but can be evaluated as renal dysfunction when applicable.  Consider the following when rating BPH:\nBPH and some types of treatment for BPH, such as alpha blocker drugs, finasteride, or balloon dilation, can cause incontinence.\nRetrograde ejaculation can result from some types of BPH treatment, especially transurethral resection of the prostate (TURP).\nSpecial monthly compensation (SMC) (k) may be warranted if there is associated erectile dysfunction (\nED)\nor retrograde ejaculation as a result of treatment or if hormone therapy is used.  SMC entitlement is determined on a factual basis.\nV.iii.7.3.b\n.\nDiagnosis of Prostate Cancer by Biopsy\nA diagnosis of prostate cancer is made only on the basis of a prostate biopsy.  An elevated prostate-specific antigen (PSA) test is\nnot\ndiagnostic of cancer.\nException\n:\nA prostate biopsy is not required to support a medical diagnosis that prostate cancer has recurred after radical prostatectomy.\nWhen the initial diagnosis of prostate cancer was confirmed by biopsy and the evidence shows recurrence following any type of treatment, repeat biopsy is not required.\nThe fact that the diagnosis of recurrence considered PSA does not make the assessment insufficient for rating purposes.  An assessment should, however, be based on more than PSA results such as, but not limited to, other clinical findings, reports of symptoms, or other medical evidence\nV.iii.7.3.c\n.\nRating Prostate Cancer\nThe table below describes common treatments for prostate cancer as well as the side effects and rating considerations associated with the treatment.\nType of Treatment\nPotential Side Effects\nRating Considerations\nWatchful waiting\nalso called\nconservative management\nobservation, or\nsurveillance, and\nno immediate specific therapy is being used, but cancer is active.\nNone, except for the continued presence and potential metastasis of cancer\noften used when life expectancy is short due to age or other illness since prostate cancer is slow- growing.\nReview to confirm the continuation of active cancer previously confirmed by biopsy.\nEvaluate at 100 percent, despite the lack of treatment and possible lack of symptoms.\nNote\n:  If watchful waiting is used to closely monitor inactive cancer that is in remission, evaluate based on residuals since the cancer is no longer active.\nRadical prostatectomy surgery which\nis characterized by removal of the prostate gland and seminal vesicles\nis the most common treatment for localized cancer\ncan be curative, and\nmay involve a nerve-sparing procedure to improve chances that the patient will retain normal erectile function.\nImpotence, and/or\nincontinence.\nIn all cases of radical prostatectomy, award SMC (k) for\nloss of use (\nLOU) of a creative organ.\nConsider\nservice connection (\nSC) for ED on a facts-found basis.\nCryotherapy\n, also known as cryosurgery or cryoablation, is a procedure by which the prostate and nearby tissues are frozen with liquid nitrogen via probes in the perineum.\nImpotence\nincontinence\nurethral scarring, and\nrectourethral fistula (rare).\nConsider SMC (k) on a facts-found basis.\nRadiation\ncan be curative if cancer is confined to the prostate and surrounding tissues and PSA is 15 nanograms (ng)/ml or less\nis also used as palliative therapy to relieve symptoms of advanced cancer, such as bone pain due to metastasis, and\ncan be\ninternal radiation therapy, or brachytherapy, in which radioactive seeds are implanted in the prostate, including\nhigh dose radiation (HDR) in which seeds are implanted for less than a day and then removed, and radiation is present only while seeds are in place, or\nlow dose radiation (LDR) in which seeds are permanently implanted and give off radiation for weeks to months, depending on the radioisotope used, or\nexternal radiation therapy, in which radiation is delivered by high-energy eternal radiation for six to eight weeks.\nAfter external beam radiation\nimpotence, and/or\nincontinence, and\nafter brachytherap\ny\nimpotence\nincontinence\nbowel problems, and/or\nurethral complications.\nAfter internal HDR\nthe radiation continues only for hours or days, so a six-month assignment of temporary 100-percent under\n38 CFR 4.115b, DC 7528\nis appropriate, and\nconsider SMC (k) for impotence on a facts-found basis.\nAfter internal LDR\nthe effective radiation should be gone by one year\nassign a 100-percent evaluation for one year, and\nschedule a review exam six months following the cessation of the one-year treatment period.\nNote\n:  If radiation is used only as palliative therapy in advanced cancer, the 100-percent evaluation will continue because the cancer will remain active.  Therefore\nreview for metastatic disease, and\nconsider permanency.\nHormone therapy is primarily for palliation of prostate cancer which is not confined to the prostate for the purpose of testosterone deprivation.\nTypes of hormone therapy include\norchiectomy\n, the removal of testes to prevent testosterone production\nluteinizing hormone releasing hormone agonists (LHRH analogs), which can lower the testosterone as effectively as orchiectomy such as\nLupron (leuprolide)\nZoladex (goserelin), and\nbusrelin\nestrogens or estrogen-like drugs, which lower the level of testosterone\nsecond-line hormonal drugs, which are used when first-line hormone therapy fails\nanti-androgens, which block the ability of the body to use androgens, such as\nEulexin (flutamide)\nCasodex (bicalutamide), and\nNilandron (nilutamide), and\ncombined hormone therapy, which is an anti-androgen combined with orchiectomy or an LHRH agonist (analog).\nAfter any hormone therapy\nhot flashes\nosteoporosis\nloss of muscle mass\nafter orchiectomy\nimpotence\nsterility\nloss of sex drive\nafter anti-androgen therapy\ngastrointestinal upset\nbreast tenderness\ngynecomastia\ndecreased libido\nimpotence\nhot flashes, and\nafter LHRH analogs\nimpotence\nhot flashes, and\ngynecomastia.\nOrchiectomy results in anatomical loss of a creative organ; therefore\nevaluate under\n38 CFR 4.115b, DC 7524\n, and\naward SMC.\nHormone therapy may continue for many years; therefore\nreview treatment records for expected duration of treatment, and\nconsider permanence.\nChemotherapy\nDepending on the type of chemotherapy used, there are multiple possible side effects.\nChemotherapy is used for palliation as current agents will not eradicate prostate cancer; therefore\nevaluate as 100 percent\nconsider permanence\nreview for metastatic disease, and\nif metastatic disease affects body systems other than the genitourinary system, award a separate evaluation for confirmed metastatic disease under the appropriate code for that body system.\nReferences\n:  For more information on\nassigning staged evaluations for prostate cancer. see\nTatum v. Shinseki\n,\n24 Vet.App 139, 141 (2010)\nM21-1, Part VIII, Subpart iv, 8.D.3.e and f\n, and\nM21-1, Part V, Subpart ii, 3.D.2.j\nconsidering entitlement to SC for ED and SC for LOU of a creative organ associated with prostate cancer, see\nM21-1, Part V, Subpart iii, 7.3.d\n, and\nevaluating cancer and its residuals, see\nM21-1, Part V, Subpart ii, 3.D.5.a and b\n.\nV.iii.7.3.d\n.\nED and SMC Due to Prostate Cancer\nSC for prostate cancer does\nnot\nautomatically result in\nSC for ED, or\nentitlement to SMC (k).\nThere are various treatments for prostate cancer, such as hormonal therapy, that may result in ED.  Refer to\nM21-1, Part V, Subpart iii, 7.3.c\nfor more information about specific types of treatment and the associated side effects, such as ED or loss of use of a creative organ.\nNote\n:  General guidelines under\n38 CFR 3.400\nshould be followed when determining the effective date for ED.  If ED is the basis for SMC (k), the effective date for the SMC will generally coincide with the date SC is awarded for ED.\nException\n:  Radical prostatectomy is a special case.  In all cases where prostate cancer is treated with radical prostatectomy, award entitlement to SMC (k) for LOU of a creative organ without additional examination or medical opinion.\nRadical prostatectomy results in loss of ejaculatory power and will warrant SMC (k) from the date of the procedure, assuming that the Veteran is already SC for prostate cancer from that date.\nEntitlement to SC for ED associated with the radical prostatectomy is a separate factual determination.  For the purposes of determining SMC entitlement following radical prostatectomy, it is irrelevant whether ED also exists at the time the SMC is awarded.\nReference\n:  For more information on when SMC is warranted for ED and other sexual dysfunction, see\nM21-1, Part V, Subpart iii, 7.4.b\n.\n4\n.\nED\nIntroduction\nThis topic contains information about ED, including\nED\nSMC associated with ED or other sexual dysfunction\nED associated with systemic disease\n, and\nscars associated with ED\n.\nChange Date\nNovember 15, 2021\nV.iii.7.4.a\n.\nED\nED is evaluated with a noncompensable evaluation under\n38 CFR 4.115b, DC 7522\nwithout regard to whether penile deformity is present.\nReference\n:  For more information on evaluating deformity of the penis under the version of the rating schedule in effect prior to November 14, 2021, see\nWilliams v. Wilkie\n, 30 Vet.App. 134 (2018).\nV.iii.7.4.b\n.\nEntitlement to SMC Associated With ED\nor Other Sexual Dysfunction\nGrant SMC (k) when the evidence shows that SC ED constitutes LOU of a creative organ.  Other diagnoses of sexual dysfunction that may result in LOU include (but are not limited to) loss of libido, loss of sexual drive, or impotence.\nWhen a VA examiner finds that there is ED or other sexual dysfunction, SMC (k) is established even though\nthe Veteran can achieve erection and penetration with the use of medication, or\nthe Veteran had a vasectomy prior to the development of the LOU of a creative organ, as vasectomies may be reversible while LOU is not.\nWhen the evidence, including an examination report or other medical information, shows that a diagnosis of ED or other sexual dysfunction is present but indicates that the Veteran can penetrate and ejaculate\nwithout\nthe use of medication, resolve reasonable doubt in the Veteran’s favor and interpret the report to establish that LOU of a creative organ is present and grant entitlement to SMC (k).\nException\n:  Do\nnot\nestablish SMC(k) based on an examiner’s finding/conclusion that there is ED if\nthe examination is insufficient for rating purposes because it is not supported by a valid rationale and/or by the evidence of record (for example if the examiner checks that there is ED but there is no history, examination or other basis for the finding)\nthe report is based on the claimant’s report of ED but there is some specific evidence that the claimant’s account of ED lacks credibility, or\nthe preponderance (greater weight) of the evidence proves the contrary.\nReferences\n:  For more information on\nentitlement to SMC (k) for LOU of a creative organ, see\n38 CFR 3.350(a)(1)\n, and\nM21-1, Part VIII, Subpart iv, 4.A.4\nentitlement to SMC (k) associated with radical prostatectomy for prostate cancer, see\nM21-1, Part V, Subpart iii, 7.3.d\n, and\nM21-1, Part VIII, Subpart iv, 4.A.4.c\nevaluating ED, see\n38 CFR 4.115b, DC 7522\n, and\ninsufficient examination reports, see\nM21-1, Part IV, Subpart i, 3.C\n, and\nprocedures for evaluating evidence, see\nM21-1, Part V, Subpart ii, 1.A\n.\nV.iii.7.4.c\n.\nED Associated With Systemic Disease\nWhen evaluating residuals of a systemic disease process such as multiple sclerosis or amyotrophic lateral sclerosis and associated ED, award SC for ED and assign a separate evaluation for the ED when it is otherwise appropriate to separately evaluate residuals.\nException\n:  Noncompensable complications of diabetes mellitus must be evaluated with the disease process as provided in\n38 CFR 4.119, DC 7913\n.\nReference\n:  For more information on the assignment of a separate evaluation for ED associated with systemic disease processes, see\nM21-1, Part V, Subpart iii, 12.C\n.\nV.iii.7.4.d\n.\nScars Associated With ED\nEvaluations for ED assigned under\n38 CFR 4.115b, DC 7522\naccount for the functional impairment arising from disease or traumatic injury.  Evaluation under this DC does not preclude a separate evaluation for non-functional impairment, such as painful scarring, under\n38 CFR 4.118\nwhen otherwise warranted.\n5\n.\nOther Genitourinary Considerations\nIntroduction\nThis topic contains information about other genitourinary considerations, including\nresiduals of venereal disease or human immunodeficiency virus (HIV)-related illness\nkidney donation\n, and\nhydrocele and varicocele\n.\nChange Date\nNovember 15, 2021\nV.iii.7.5.a\n.\nResiduals of Venereal Disease or HIV-Related Illness\nDo\nnot\nconsider specific residuals of venereal disease or human immunodeficiency virus (HIV)-related illness to be the result of willful misconduct.\nDetermine SC for residuals of venereal disease or HIV-related illness by the same general principles applicable to resolution of the issue of SC for other diseases.\nReferences\n:  For more information on\nwillful misconduct and venereal disease, see\n38 CFR 3.301(c)(1)\nconsidering claims for SC of human papillomavirus infection (HPV), see\nM21-1, Part V, Subpart iii, 8.A.2.f\n, and\ndisability or death from use of drugs, see\nM21-1, Part X, Subpart iv, 1.D\n.\nV.iii.7.5.b\n.\nKidney Donation\nKidney donation and any expected residual effects thereof are\nnot\nsubject to SC. Kidney donation is considered an elective surgery, and therefore, does not meet the provisions of a disease or injury incurred coincident with service.\nReference\n:  For more information about the principles relating to SC, see\n38 CFR 3.303\n, and\nM21-1, Part V, Subpart ii, 2.A\n.\nV.iii.7.5.c\n.\nHydrocele and Varicocele\nHydrocele\nis a collection of fluid in the scrotum.\nVaricocele\nis a dilatation of the veins along the cord that receives blood from the testicles.\nThese conditions may be associated with a decrease in fertility and, in rare instances, may be associated with infertility.  In instances where there is a clinical finding of infertility which is linked to the hydrocele or varicocele, entitlement to SMC is warranted.\n<-- Previous Section\nNext Section -->\nTo Top",
  "content_html": "<div class=\"article-content\">\n<div compile-custom=\"article.content\" ng-aria=\"articleContent\"><p class=\"ng-scope\"></p><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000014523\" articlename=\"M21-1, Part V, Subpart iii, Chapter 6 - Digestive Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014523/M21-1-Part-V-Subpart-iii-Chapter-6-Digestive-Disabilities\">&lt;-- Previous Section</a> <a articleid=\"554400000180511\" articlename=\"M21-1, Part V, Subpart iii, Chapter 8, Section A - Disabilities of the Gynecological System\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180511/M21-1-Part-V-Subpart-iii-Chapter-8-Section-A-Disabilities-of-the-Gynecological-System\">Next Section --&gt;</a></span></span></p><h2 class=\"ng-scope\"><a id=\"top\" name=\"top\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">Overview</span></span></a></h2><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">In This Chapter</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This chapter contains the following topics:</span></span></div><div></div><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"height: 0px; width: 500px; border-spacing: 0px; border-collapse: revert;\" summary=\"Column 1 has the topic number and column 2 has the topic title.\"><thead><tr><th scope=\"col\" style=\"width: 86px; padding: 0px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Topic</strong></span></span></div></th><th scope=\"col\" style=\"width: 423px; padding: 0px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Topic Name</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 86px; padding: 0px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">1 </span></span></div></td><td style=\"width: 423px; vertical-align: middle; padding: 0px;\"><div><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1\" target=\"_self\"><span style=\"font-size: 14px\">General Rating Principles for Genitourinary Disabilities</span></a></span></div></td></tr><tr><td style=\"width: 86px; text-align: center; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">2</span></span></div></td><td style=\"width: 423px; vertical-align: middle; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#2\" target=\"_self\">Evaluating Nephritis and Nephropathy</a></span></span></div></td></tr><tr><td style=\"width: 86px; padding: 0px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">3</span></span></div></td><td style=\"width: 423px; padding: 0px;\"><a href=\"#3\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Prostate Conditions</span></span></a></td></tr><tr><td style=\"width: 86px; padding: 0px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">4</span></span></div></td><td style=\"width: 423px; padding: 0px;\"><a href=\"#4\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Erectile Dysfunction (ED)</span></span></a></td></tr><tr><td style=\"width: 86px; text-align: center; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">5</span></span></div></td><td style=\"width: 423px; padding: 0px;\"><a href=\"#5\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Other Genitourinary Considerations</span></span></a></td></tr></tbody></table><div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">       </span></span><br/> </div><h2 class=\"ng-scope\"><br/><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">1<a id=\"1\" name=\"1\">.</a>  General Rating Principles for Genitourinary Disabilities</span></span></h2><p class=\"ng-scope\"> <br/>  <br/> </p><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains guidance on the general principles for evaluating genitourinary dysfunction, including</span></span></p><ul><li><a href=\"#1a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">rating genitourinary disorders</span></span></a></li><li><a href=\"#1b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">renal dysfunction</span></span></a></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#1c\" target=\"_self\">determining the chronicity of renal dysfunction</a></span></span></li><li><a href=\"#1d\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">use of catheters and other appliances</span></span></a></li><li><a href=\"#1e\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">urinary tract infection </span></span></a></li><li><a href=\"#1f\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">recurrent stone formation</span></span></a>, and</li><li><a href=\"#1g\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">changes in the rating schedule for the genitourinary system</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">November 15, 2021</span></span></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>V.iii.7.1.a<a id=\"1a\" name=\"1a\">.</a>  Rating Genitourinary Disorders</strong></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">The diagnostic codes (DCs) for genitourinary disorders are at <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=4cc8543fd8f53bd5c478fce653e7430d&amp;mc=true&amp;node=se38.1.4_1115b&amp;rgn=div8http://www.ecfr.gov/cgi-bin/text-idx?SID=4cc8543fd8f53bd5c478fce653e7430d&amp;mc=true&amp;node=se38.1.4_1115b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115b</a>.  Many of those are rated by the rating formulas for dysfunction provided in <a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=81b516116b4e110561af986fced965c2&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_1115a\" target=\"_blank\">38 CFR 4.115a</a>.  The three types of genitourinary dysfunction are</span></span></div><ul><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">voiding dysfunction, which provides evaluations based on</span></span></div><ul><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">frequency</span></span></div></li><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">leakage, and/or</span></span></div></li><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">obstructed voiding</span></span></div></li></ul></li><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">urinary tract infections, and</span></span></div></li><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">renal dysfunction.</span></span></div></li></ul><div class=\"MsoBlockText\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=81b516116b4e110561af986fced965c2&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_1115a\" target=\"_blank\">38 CFR 4.115a</a> provides that diseases of the genitourinary system generally result in disabilities related to renal or voiding dysfunctions, infections, or a combination of these.</span></span></div><ul><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Where a particular DC lists more than one dysfunction under which the condition can be rated, only the predominant area of dysfunction shall be utilized for rating purposes.  Separate evaluations may not be assigned for different types of dysfunction attributable to a single condition.</span></span></div></li><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">When different genitourinary conditions are present and each is evaluated using a different type of dysfunction, separate evaluations may be assigned.</span></span></div></li><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">When different genitourinary conditions are present but each is evaluated using the same type of dysfunction, separate evaluations may not be assigned.</span></span></div></li></ul></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Important</strong></em>:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Ensure in every case that rating decisions not pyramid or separate individual findings when those findings in their entirety constitute one disability as discussed at <a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\">M21-1, Part V, Subpart ii, 3.D.2.b</a>. </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=ca6780f87ddf9e811ae2485e04ad8d0a&amp;mc=true&amp;node=se38.1.4_1115a&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115a</a> acknowledges that since the areas of dysfunction do not cover all symptoms resulting from genitourinary diseases, specific diagnoses may include a description of symptoms assigned to that diagnosis.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Example</em></strong>:  For pyelonephritis, <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=4cc8543fd8f53bd5c478fce653e7430d&amp;mc=true&amp;node=se38.1.4_1115b&amp;rgn=div8http://www.ecfr.gov/cgi-bin/text-idx?SID=4cc8543fd8f53bd5c478fce653e7430d&amp;mc=true&amp;node=se38.1.4_1115b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115b, DC 7504</a> directs to rate as renal dysfunction or urinary tract infection, whichever is predominant.  If symptoms of both renal dysfunction and urinary tract infection are present and associated with pyelonephritis, assign a single evaluation based on the most disabling symptoms. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.7.1.b<a id=\"1b\" name=\"1b\">.</a>  Renal Dysfunction</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"tab-stops: 6.5in\">Renal dysfunction is evaluated using specific, objective laboratory findings.</span></span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Glomerular filtration rate (GFR) is widely accepted as the best overall measure of kidney function in health and disease.  There is an inverse correlation between GFR and functional impairment.</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Lower GFRs correspond to greater impairment.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Individuals with GFRs less than 60 mL/min/1.73 m<sup>2</sup> are considered to have chronic renal disease.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">A GFR less than 15 mL/min/1.73 m<sup>2</sup> is a sign of renal failure. </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">GFR, estimated GFR (eGFR), and creatinine-based approximations are acceptable for evaluation purposes, as each has been shown to be an adequate indicator of the stage of chronic kidney disease.  Elevated creatinine levels are correlated with decreasing GFR.</span></span></li></ul></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Proteinuria, as measured by increased urinary excretion of albumin, is an early and sensitive maker of kidney damage and is reflected by an albumin/creatinine ratio (ACR) of 30 mg/g or greater.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.7.1.c<a id=\"1c\" name=\"1c\">.</a>  Determining Chronicity of Renal Dysfunction</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Assignment of a compensable evaluation for renal dysfunction based on abnormal GFR or (other findings accepted for evaluation purposes under <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR8198d98a7a48906/section-4.115a\" target=\"_blank\">38 CFR 4.115a</a>) is premised upon findings spanning over three consecutive  months. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Satisfaction of the three-month requirement does not necessitate an individual finding in each month of a three-month period.  Rather, clinical data showing an abnormal finding with another repeated abnormal finding 3 or more months later during a 12-month period will document chronicity of the impairment and will be sufficient to satisfy this requirement unless there is evidence to the contrary.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">It is expected that an individual with chronic renal dysfunction would be followed for treatment and clinical data would be sufficient to document chronicity of findings over the three month or longer period. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">However, when such clinical data is unavailable to decision makers, a one-time finding may be used to assign the corresponding disability evaluation unless there is evidence that suggests non-chronicity of the impairment. </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">When a compensable evaluation is assigned based on a one-time finding of abnormal GFR, defer the end product and schedule an at-once examination to obtain a second GFR reading three months after the first. </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">This at-once examination is necessary to satisfy the regulatory requirement for sustained findings from a three-month period.</span></span></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b><i>Reference</i></b>:  For more information on handling improvement shown on the at-once examination, see</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR63da83ba671b92b/section-3.105#p-3.105(e)\" target=\"_blank\">38 CFR 3.105(e)</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a articleid=\"554400000177969\" articlename=\"M21-1, Part X, Subpart ii, Chapter 4, Section A - Rating Decisions for Reduction Due to Improvement\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177969/M21-1-Part-X-Subpart-ii-Chapter-4-Section-A-Rating-Decisions-for-Reduction-Due-to-Improvement\">M21-1, Part X, Subpart ii, 4.A</a>.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>V.iii.7.1.d<a id=\"1d\" name=\"1d\">.</a> Use of Catheters and Other Appliances</strong></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The term <strong><em>appliance</em></strong>, as used in the criteria for voiding dysfunction under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=f0927e0449515a9d9a73c8c631159550&amp;mc=true&amp;node=se38.1.4_1115a&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115a</a>, includes <em>all</em> types of catheters, as well as any other assistive device for urination.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Important</em></strong>:  Appliances, including catheters, may be used to treat urine leakage associated with voiding dysfunction and/or urine retention associated with obstructed voiding.  The rating activity should review the evidence carefully to determine whether the appliance is required to treat urine leakage or urine retention and evaluate on the predominant disability.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Note</strong></em>:  For the purposes of evaluating urinary tract infection at the 30-percent rate, the use of catheters is not considered comparable to drainage by stent or nephrostomy and is inconsistent with the remainder of the criteria required for a 30-percent evaluation.  Stent and nephrostomy tube insertion are surgical procedures and require more intensive management than drainage by catheterization. </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Example 1</em></strong>:  A Veteran is </span><span style=\"font-family: arial, helvetica, sans-serif\">service-connected (</span><span style=\"font-family: arial , helvetica , sans-serif\">SC) for a bladder injury.  Medical records show a catheter is required for <em>urine leakage</em> due to the bladder injury.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Result</em></strong>:  A 60-percent evaluation should be assigned for this disability based on voiding dysfunction.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Example 2</em></strong>:  A Veteran is SC for a bladder injury. Medical records show a catheter is required for <em>urine retention</em> due to the bladder injury.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Result</em></strong>:  A 30-percent evaluation should be assigned for this disability based on obstructed voiding.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on ratings of the genitourinary system based on voiding dysfunction, see <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=f0927e0449515a9d9a73c8c631159550&amp;mc=true&amp;node=se38.1.4_1115a&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115a</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.7.1.e<a id=\"1e\" name=\"1e\">.</a>  Urinary Tract Infection</span></span></span></span></strong></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">The following terms are utilized in the criteria for evaluating urinary tract infection.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b><i>Suppressive drug therapy</i></b>, as identified in the criteria for the 0- and 10-percent disability evaluations, refers to the use of prolonged suppressive antibiotic therapy or medications for treatment of urinary tract infections.  The required duration of the therapy is identified in the rating criteria. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b><i>Continuous intensive management</i></b>, as identified in the criteria for the 30-percent disability evaluation, refers to the requirement for treatment beyond the use of antibiotic or other medications or hospitalizations as described in the 0- and 10-percent evaluation levels.  Examples of this level of care include but are not limited surgical management of the nephrostomy and/or stent, intravenous antibiotics, or treatment that is otherwise required for the maintenance of the nephrostomy tube or stent.  </span></span></div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.7.1.f<a id=\"1f\" name=\"1f\">.</a>  Recurrent Stone Formation</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Under <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR8198d98a7a48906/section-4.115#p-4.115(b)\" target=\"_blank\">38 CFR 4.115b, DC 7508</a>, a 30-percent disability evaluation is assigned when evidence shows recurrent stone formation requiring invasive or non-invasive procedures more than 2 times per year.</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Examples of therapeutic procedures that would satisfy these requirements include (but are not limited to)</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">invasive procedures, such as</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">open surgical lithotomy</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">percutaneous nephrolithotomy (PCNL)</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">retrograde intrarenal surgery (RIRS), or</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">other minimally invasive endourological treatments, and</span></span></li></ul></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">non-invasive procedures, such as</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">shockwave lithotripsy (SWL), or</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">ureteroscopic fragmentation and retrieval.</span></span></li></ul></li></ul></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Recurrent stone formation means that there must be more than one episode of stone formation requiring treatment during a one-year period.</span></span></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.7.1.g<a id=\"1g\" name=\"1g\">.</a>  Changes in the Rating Schedule for the Genitourinary System </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">The rating criteria for the genitourinary system have undergone historical changes.  Recent full-scale revisions were effective on the following dates:</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">November 14, 2021, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">February 17, 1994.</span></span></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b><i>Note</i></b>:  These changes in the rating criteria</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">are not considered liberalizing, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">should not be the basis for a reduction in disability rating unless medical evidence establishes that the disability has actually improved.  </span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><h2 class=\"ng-scope\"><br/><br/><strong><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">2<a id=\"2\" name=\"2\">.</a>  Evaluating Nephritis and Nephropathy</span></span></strong></h2><p class=\"ng-scope\"> <br/>  <br/> </p><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains information about general principles for rating genitourinary disabilities, including</span></span></p><ul><li><a href=\"#2a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">definition of nephropathy</span></span></a></li><li><a href=\"#2b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">evaluating nephropathy</span></span></a></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#2c\" target=\"_self\">evaluation of nephropathy and hypertension</a></span></span></li><li><a href=\"#2d\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">definition of nephritis</span></span></a></li><li><a href=\"#2e\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">characteristics of nephritis</span></span></a></li><li><a href=\"#2f\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">evaluating nephritis</span></span></a></li><li><a href=\"#2g\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">limits on separate evaluation of nephritis and cardiovascular conditions</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">, and</span></span></li><li><a href=\"#2h\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">distinguishing nephritis from other types of nephropathy</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">November 15, 2021</span></span></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>V.iii.7.2.a<a id=\"2a\" name=\"2a\">.</a>  Definition:  Nephropathy</strong></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Nephropathy</em></strong> is generally defined as a condition encompassing disease or damage of the kidneys.  Nephropathy is a broader term to describe any condition that impairs renal function. Examples of nephropathy include (but are not limited to) chronic renal disease, nephrotic syndrome, and nephritis.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>V.iii.7.2.b<a id=\"2b\" name=\"2b\">.</a>  Evaluating Nephropathy</strong></span></span></h3></td><td style=\"height: 8px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"height: 0px; width: 512px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">For Department of Veterans Affairs (VA) disability purposes, nephropathy is evaluated as renal dysfunction under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=54c96c965aea2c1b50e0224171bc3e6e&amp;mc=true&amp;node=se38.1.4_1115a&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115a</a>.</span></span></div><div></div><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">The most commonly used DC for nephropathy is <a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=222ee19dbafbd3e428f19ca334315408&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_1115b\" target=\"_blank\">38 CFR 4.115b, DC 7541</a>, “renal involvement in diabetes mellitus type I or II,” otherwise known as</span></span> <span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">diabetic nephropathy. </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b><i>Important</i></b>:  When the renal impairment is a form of nephritis, <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR8198d98a7a48906/section-4.115\" target=\"_blank\">38 CFR 4.115</a> applies as discussed in <a href=\"#2f\" target=\"_self\">M21-1, Part V, Subpart iii, 7.2.f</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.7.2.c<a id=\"2c\" name=\"2c\">.</a>  Evaluation of Nephropathy and <strong>Hypertension</strong></span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"tab-stops: 6.5in\">The provision of <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR8198d98a7a48906/section-4.115\" target=\"_blank\">38 CFR 4.115</a> <span style=\"color: black\">that</span> states that separate ratings are not to be assigned for disability from disease of the heart and any form of nephritis does not apply when evaluating other types of nephropathy because nephropathy is a broader diagnostic classification warranting its own evaluative approach.  Other types of nephropathy may be assigned separate evaluations for the renal impairment and heart disease and/or hypertension.</span></span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"tab-stops: 6.5in\"><b><i>Note</i></b>:  Prior to the revision of <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=3ef32e0ff149cd613c9936c7ba66cbad&amp;mc=true&amp;node=se38.1.4_1115a&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115a</a> effective on November 14, 2021, hypertension was included among the criteria for evaluation of renal dysfunction.  Consequently, under the historical criteria, separate evaluations could not be assigned for hypertension and nephropathy <i>except </i>when dialysis was required or when the condition was characterized by absence of the kidney as assignment of separate evaluations would have been in violation of <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.14\" target=\"_blank\">38 CFR 4.14</a>.</span></span></span></div></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on the historical prohibition against separate evaluations for hypertension and nephropathy in place prior to November 14, 2021, see</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.14\">38 CFR 4.14</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">the attachment titled <em>Historical_M21-1V_iii_7_9-15-21</em>.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.7.2.d<a id=\"2d\" name=\"2d\">.</a>  Definition:  Nephritis</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Nephritis </em></strong>is generally defined as inflammation of the kidneys.  It includes inflammation of any renal structure such as glomeruli, tubules, or interstitial tissue. Nephritis is a form of nephropathy.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>V.iii.7.2.e<a id=\"2e\" name=\"2e\">.</a>  Characteristics of Nephritis</strong></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=54c96c965aea2c1b50e0224171bc3e6e&amp;mc=true&amp;node=se38.1.4_1115&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115</a> discusses several medical concepts pertaining to nephritis. These concepts may be useful in determining when the duty to assist requires an examination or opinion or when medical results may need clarification.</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Characteristics of glomerular nephritis</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Usually preceded by or associated with severe infectious disease.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Sudden onset.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Course marked by red blood cells, salt retention, and edema.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">May clear up entirely or progress to a chronic condition.</span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Characteristics of nephrosclerotic nephritis</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Originating in hypertension or arteriosclerosis.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Develops slowly.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Minimum laboratory findings.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Associated with natural progress.<span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"> </span></span></span></span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Albuminuria alone is not nephritis. </span></span></span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Do not accept the presence of transient symptoms, such as elevated albumin and the presence of casts following febrile illness as establishing nephritis.  </span></span></span></span></span></span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.7.2.f<a id=\"2f\" name=\"2f\">.</a>  Evaluating Nephritis</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Chronic nephritis is addressed in <a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=81b516116b4e110561af986fced965c2&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_1115b\" target=\"_blank\">38 CFR 4.115b, DC 7502</a>.  It is rated as renal dysfunction under <a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=81b516116b4e110561af986fced965c2&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_1115a\" target=\"_blank\">38 CFR 4.115a</a>.  Glomerulonephritis (<a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=81b516116b4e110561af986fced965c2&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_1115b\" target=\"_blank\">38 CFR 4.115b, DC 7536</a>) and interstitial nephritis (<a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=81b516116b4e110561af986fced965c2&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_1115b\" target=\"_blank\">38 CFR 4.115b, DC 7537</a>) also use the renal dysfunction criteria.  </span></span><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  When nephrosclerosis arises from nephritis, the evaluation criteria under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=fc5847cf90d70d828fac9668b29a7975&amp;mc=true&amp;node=se38.1.4_1115b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115b, DC 7507</a> directs that</span></span></span></span></div><div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">nephrosclerosis be rated according to the predominant symptoms as</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">renal dysfunction</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">hypertension, or</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">heart disease, and</span></span></li></ul></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">if nephrosclerosis is rated under the cardiovascular schedule, the rating which would otherwise be assigned will be elevated to the next higher level.</span></span></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>V.iii.7.2.g<a id=\"2g\" name=\"2g\">.</a>  Limits on Separate Evaluation of Nephritis and Cardiovascular Conditions</strong></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=54c96c965aea2c1b50e0224171bc3e6e&amp;mc=true&amp;node=se38.1.4_1115&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115</a> states that separate ratings cannot be assigned for disability from disease of the heart and any form of nephritis.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The rationale is that there is a close interrelationship between cardiovascular disabilities and nephritis.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Example 1</em></strong>:  The following separate evaluations are <strong><em>not</em></strong> permitted under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=54c96c965aea2c1b50e0224171bc3e6e&amp;mc=true&amp;node=se38.1.4_1115&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115</a> <strong><em>even if</em></strong> the nephritis evaluation was supportable based on definite decrease in renal function.</span></span></div><div></div><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-spacing: 0px; border-collapse: revert;\" summary=\"An example of rating code.\"><tbody><tr><td style=\"width: 65px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">7101</span></span></div></td><td style=\"width: 266px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Hypertension</span></span></div></td><td style=\"width: 40px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">10</span></span></div></td></tr><tr><td style=\"width: 65px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">7502</span></span></div></td><td style=\"width: 266px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Nephritis</span></span></div></td><td style=\"width: 40px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">60</span></span></div></td></tr></tbody></table><div> <span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Exceptions</em></strong>:  Separate ratings for any hypertension or heart disease are permitted in the following scenarios:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">chronic renal disease has progressed to the point where regular dialysis is required, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">if absence of a kidney is the sole renal disability, even if removal was required because of nephritis.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Example 2</em></strong>:</span></span>  <span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The following separate evaluations are allowed since absence of the kidney is the sole renal disability. </span></span></div><div></div><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-spacing: 0px; border-collapse: revert;\" summary=\"An example of rating code.\"><tbody><tr><td style=\"width: 65px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">7500</span></span></div></td><td style=\"width: 266px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Kidney – removal of one, history of glomerulonephritis</span></span></div></td><td style=\"width: 40px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">30</span></span></div></td></tr><tr><td style=\"width: 65px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">7101</span></span></div></td><td style=\"width: 266px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Hypertension</span></span></div></td><td style=\"width: 40px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">20</span></span></div></td></tr></tbody></table><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Example 3</em></strong>:  The following separate evaluations are allowed if the 100-percent evaluation for nephritis is based on the requirement for dialysis.</span></span></div><div></div><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-spacing: 0px; border-collapse: revert;\" summary=\"An example of rating code.\"><tbody><tr><td style=\"width: 65px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">7530</span></span></div></td><td style=\"width: 266px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Nephritis</span></span></div></td><td style=\"width: 40px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">100</span></span></div></td></tr><tr><td style=\"width: 65px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">7101</span></span></div></td><td style=\"width: 266px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Hypertension</span></span></div></td><td style=\"width: 40px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">10</span></span></div></td></tr></tbody></table><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on nephritis, including the different types of nephritis, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=54c96c965aea2c1b50e0224171bc3e6e&amp;mc=true&amp;node=se38.1.4_1115&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2f\" target=\"_self\">M21-1, Part V, Subpart iii, 7.2.f</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.7.2.h<a id=\"2h\" name=\"2h\">.</a>  Distinguishing Nephritis From Other Types of Nephropathy </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Although a condition may be diagnosed as nephropathy, the evidence must be carefully examined to determine if the diagnosed nephropathy can be clinically recognized as a form of nephritis that would trigger <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR8198d98a7a48906/section-4.115\" target=\"_blank\">38 CFR 4.115</a> application.</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">A nephropathy diagnosis is not dispositive for the purpose of making this distinction. </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Additional review of the evidence beyond the given diagnosis will be necessary to determine whether the renal condition, irrespective of the diagnosis, is a form of nephritis.</span></span></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">In the following examples, the diagnosis contains the term “nephropathy” but the disability is actually a type of nephritis and must be evaluated with consideration of <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR8198d98a7a48906/section-4.115\" target=\"_blank\">38 CFR 4.115</a>.</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">IgA nephropathy is generally characterized clinically as a type of primary glomerulonephritis.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR8198d98a7a48906/section-4.115b\" target=\"_blank\">38 CFR 4.115b, DC 7537</a> is the DC for interstitial nephritis, and gouty nephropathy is identified as a type of interstitial nephritis as well as other disorders of calcium metabolism.</span></span></li></ul><p><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b><i>Important</i></b>: </span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">When the clinical evidence is unclear, request a medical opinion to determine whether the disability in question is a type of nephritis.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">It is impermissible to evaluate a type of nephritis specifically identified in the rating schedule, such as gouty nephropathy, by analogy in an effort to achieve a higher disability evaluation. </span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">       </span></span><br/> </div><p class=\"ng-scope\"></p><p class=\"ng-scope\"></p><p class=\"ng-scope\"><strong><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">3<a id=\"3\" name=\"3\">.</a>  Prostate Conditions</span></span></strong></p><p class=\"ng-scope\"> <br/> </p><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This topic contains information about prostate conditions, including</span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#3a\" target=\"_self\">benign prostatic hypertrophy (BPH)</a></span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#3b\" target=\"_self\">diagnosis of prostate cancer by biopsy</a></span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#3c\" target=\"_self\">rating prostate cancer</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#3d\" target=\"_self\">ED and special monthly compensation (SMC) due to prostate cancer</a>.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">June 14, 2019</span></span></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.7.3.a<a id=\"3a\" name=\"3a\">.</a>  BPH</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Benign prostatic hypertrophy (BPH) is evaluated under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=6c3a70b2672bd39e52a4f1bf53f43098&amp;mc=true&amp;node=se38.1.4_1115b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115b, DC 7527</a> based on associated voiding dysfunction or urinary tract infection, but can be evaluated as renal dysfunction when applicable.  Consider the following when rating BPH:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">BPH and some types of treatment for BPH, such as alpha blocker drugs, finasteride, or balloon dilation, can cause incontinence.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Retrograde ejaculation can result from some types of BPH treatment, especially transurethral resection of the prostate (TURP).</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Special monthly compensation (SMC) (k) may be warranted if there is associated erectile dysfunction (</span><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-family: arial, helvetica, sans-serif\">ED) </span>or retrograde ejaculation as a result of treatment or if hormone therapy is used.  SMC entitlement is determined on a factual basis.</span></span></span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.7.3.b<a id=\"3b\" name=\"3b\">.</a></span></span><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> Diagnosis of Prostate Cancer by Biopsy</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">A diagnosis of prostate cancer is made only on the basis of a prostate biopsy.  An elevated prostate-specific antigen (PSA) test is <strong><em>not</em></strong> diagnostic of cancer.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Exception</em></strong>:  </span><span style=\"font-family: arial, helvetica, sans-serif\">A prostate biopsy is not required to support a medical diagnosis that prostate cancer has recurred after radical prostatectomy.  </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When the initial diagnosis of prostate cancer was confirmed by biopsy and the evidence shows recurrence following any type of treatment, repeat biopsy is not required.  </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The fact that the diagnosis of recurrence considered PSA does not make the assessment insufficient for rating purposes.  An assessment should, however, be based on more than PSA results such as, but not limited to, other clinical findings, reports of symptoms, or other medical evidence</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.7.3.c<a id=\"3c\" name=\"3c\">.</a></span></span><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> Rating Prostate Cancer</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The table below describes common treatments for prostate cancer as well as the side effects and rating considerations associated with the treatment.</span></span></div><div></div><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"height: 3153px; width: 498px; border-spacing: 0px; border-collapse: revert;\" summary=\"Column 1 provide the type of treatment, column 2 provides the potential side effects, and column 3 provides rating considerations.\" width=\"498\"><thead><tr><th scope=\"col\" style=\"width: 174px; padding: 0px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Type of Treatment</strong></span></span></span></span></div></th><th scope=\"col\" style=\"width: 162px; padding: 0px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Potential Side Effects</strong></span></span></span></span></div></th><th scope=\"col\" style=\"width: 174px; padding: 0px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Rating Considerations</strong></span></span></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 174px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Watchful waiting</span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">also called</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">conservative management</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">observation, or</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">surveillance, and</span></span></span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">no immediate specific therapy is being used, but cancer is active.</span></span></span></span></div></li></ul></td><td style=\"width: 174px; vertical-align: top; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">None, except for the continued presence and potential metastasis of cancer</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">often used when life expectancy is short due to age or other illness since prostate cancer is slow- growing.</span></span></span></span></div></li></ul></td><td style=\"width: 174px; vertical-align: top; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Review to confirm the continuation of active cancer previously confirmed by biopsy.</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Evaluate at 100 percent, despite the lack of treatment and possible lack of symptoms.</span></span></span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Note</em></strong>:  If watchful waiting is used to closely monitor inactive cancer that is in remission, evaluate based on residuals since the cancer is no longer active. </span></span></span></span></div></td></tr><tr><td style=\"width: 174px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Radical prostatectomy surgery which </span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">is characterized by removal of the prostate gland and seminal vesicles</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">is the most common treatment for localized cancer</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">can be curative, and</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">may involve a nerve-sparing procedure to improve chances that the patient will retain normal erectile function.</span></span></span></span></div></li></ul></td><td style=\"width: 174px; vertical-align: top; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Impotence, and/or</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">incontinence.</span></span></span></span></div></li></ul></td><td style=\"width: 174px; vertical-align: top; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">In all cases of radical prostatectomy, award SMC (k) for </span></span></span><span style=\"font-family: arial, helvetica, sans-serif\">loss of use (</span><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">LOU) of a creative organ.</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Consider </span></span></span><span style=\"font-family: arial, helvetica, sans-serif\">service connection (</span><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">SC) for ED on a facts-found basis.</span></span></span></span></div></li></ul></td></tr><tr><td style=\"width: 174px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Cryotherapy</em></strong>, also known as cryosurgery or cryoablation, is a procedure by which the prostate and nearby tissues are frozen with liquid nitrogen via probes in the perineum.</span></span></span></span></div></td><td style=\"width: 174px; vertical-align: top; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Impotence</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">incontinence</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">urethral scarring, and</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">rectourethral fistula (rare).</span></span></span></span></div></li></ul></td><td style=\"width: 174px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Consider SMC (k) on a facts-found basis.</span></span></span></span></div></td></tr><tr><td style=\"width: 174px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Radiation</span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">can be curative if cancer is confined to the prostate and surrounding tissues and PSA is 15 nanograms (ng)/ml or less</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">is also used as palliative therapy to relieve symptoms of advanced cancer, such as bone pain due to metastasis, and</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">can be</span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">internal radiation therapy, or brachytherapy, in which radioactive seeds are implanted in the prostate, including</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">high dose radiation (HDR) in which seeds are implanted for less than a day and then removed, and radiation is present only while seeds are in place, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">low dose radiation (LDR) in which seeds are permanently implanted and give off radiation for weeks to months, depending on the radioisotope used, or</span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">external radiation therapy, in which radiation is delivered by high-energy eternal radiation for six to eight weeks.</span></span></span></span></div></li></ul></li></ul></td><td style=\"width: 174px; vertical-align: top; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">After external beam radiation </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">impotence, and/or</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">incontinence, and</span></span></span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">after brachytherap</span></span></span></span>y</div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">impotence</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">incontinence</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">bowel problems, and/or</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">urethral complications.</span></span></span></span></div></li></ul></li></ul></td><td style=\"width: 174px; vertical-align: top; padding: 0px;\"><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">After internal HDR </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">the radiation continues only for hours or days, so a six-month assignment of temporary 100-percent under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=35ef52f6227f4eabafb59020ae1d9dbf&amp;mc=true&amp;node=se38.1.4_1115b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115b, DC 7528</a> is appropriate, and</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">consider SMC (k) for impotence on a facts-found basis.</span></span></span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">After internal LDR</span></span><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">the effective radiation should be gone by one year</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">assign a 100-percent evaluation for one year, and</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">schedule a review exam six months following the cessation of the one-year treatment period.</span></span></span></span></div></li></ul></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Note</em></strong>:  If radiation is used only as palliative therapy in advanced cancer, the 100-percent evaluation will continue because the cancer will remain active.  Therefore</span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">review for metastatic disease, and</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">consider permanency.</span></span></span></span></div></li></ul></td></tr><tr><td style=\"width: 174px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Hormone therapy is primarily for palliation of prostate cancer which is not confined to the prostate for the purpose of testosterone deprivation.</span></span></span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Types of hormone therapy include</span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>orchiectomy</em></strong>, the removal of testes to prevent testosterone production</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">luteinizing hormone releasing hormone agonists (LHRH analogs), which can lower the testosterone as effectively as orchiectomy such as</span></span> </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Lupron (leuprolide)</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Zoladex (goserelin), and</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">busrelin</span></span></span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">estrogens or estrogen-like drugs, which lower the level of testosterone</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">second-line hormonal drugs, which are used when first-line hormone therapy fails</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">anti-androgens, which block the ability of the body to use androgens, such as</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Eulexin (flutamide)</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Casodex (bicalutamide), and</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Nilandron (nilutamide), and</span></span></span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">combined hormone therapy, which is an anti-androgen combined with orchiectomy or an LHRH agonist (analog).</span></span></span></span></div></li></ul></td><td style=\"width: 174px; vertical-align: top; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">After any hormone therapy</span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">hot flashes</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">osteoporosis</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">loss of muscle mass</span></span></span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">after orchiectomy</span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">impotence</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">sterility</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">loss of sex drive</span></span></span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">after anti-androgen therapy</span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">gastrointestinal upset</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">breast tenderness</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">gynecomastia</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">decreased libido</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">impotence</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">hot flashes, and</span></span></span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">after LHRH analogs </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">impotence</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">hot flashes, and</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">gynecomastia.</span></span></span></span></div></li></ul></li></ul></td><td style=\"width: 174px; vertical-align: top; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Orchiectomy results in anatomical loss of a creative organ; therefore</span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">evaluate under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=72261cd9b25e4292a9f5a93cf52f6aa3&amp;mc=true&amp;node=se38.1.4_1115b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115b, DC 7524</a>, and</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">award SMC.</span></span></span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Hormone therapy may continue for many years; therefore</span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">review treatment records for expected duration of treatment, and</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">consider permanence.</span></span></span></span></div></li></ul></li></ul></td></tr><tr><td style=\"width: 174px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Chemotherapy</span></span></span></span></div></td><td style=\"width: 174px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Depending on the type of chemotherapy used, there are multiple possible side effects.</span></span></span></span></div></td><td style=\"width: 174px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Chemotherapy is used for palliation as current agents will not eradicate prostate cancer; therefore</span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">evaluate as 100 percent</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">consider permanence</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">review for metastatic disease, and</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">if metastatic disease affects body systems other than the genitourinary system, award a separate evaluation for confirmed metastatic disease under the appropriate code for that body system.</span></span></span></span></div></li></ul></td></tr></tbody></table><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">assigning staged evaluations for prostate cancer. see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><em><a articleid=\"554400000014490\" articlename=\"Tatum v. Shinseki, Nov 3, 2010, 24 Vet.App. 139\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014490/Tatum-v-Shinseki-Nov-3-2010-24-VetApp-139\">Tatum v. Shinseki</a></em>, </span></span><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">24 Vet.App 139, 141 (2010)</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000177543\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 8, Section D - Other Temporary Total Evaluations\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177543/M21-1-Part-VIII-Subpart-iv-Chapter-8-Section-D-Other-Temporary-Total-Evaluations\">M21-1, Part VIII, Subpart iv, 8.D.3.e and f</a>, and</span></span></div></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\">M21-1, Part V, Subpart ii, 3.D.2.j</a></span></span></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">considering entitlement to SC for ED and SC for LOU of a creative organ associated with prostate cancer, see <a href=\"#3d\" target=\"_self\">M21-1, Part V, Subpart iii, 7.3.d</a>, and</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">evaluating cancer and its residuals, see <a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\">M21-1, Part V, Subpart ii, 3.D.5.a and b</a>.</span></span></span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.7.3.d<a id=\"3d\" name=\"3d\">.</a> ED and SMC Due to Prostate Cancer</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">SC for prostate cancer does <strong><em>not</em></strong> automatically result in</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">SC for ED, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">entitlement to SMC (k).</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">There are various treatments for prostate cancer, such as hormonal therapy, that may result in ED.  Refer to <a href=\"#3c\" target=\"_self\">M21-1, Part V, Subpart iii, 7.3.c</a> for more information about specific types of treatment and the associated side effects, such as ED or loss of use of a creative organ. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  General guidelines under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=f93b52b98906ac6c4e0978043b1b051a&amp;mc=true&amp;node=se38.1.3_1400&amp;rgn=div8\" target=\"_blank\">38 CFR 3.400</a> should be followed when determining the effective date for ED.  If ED is the basis for SMC (k), the effective date for the SMC will generally coincide with the date SC is awarded for ED.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Exception</em></strong>:  Radical prostatectomy is a special case.  In all cases where prostate cancer is treated with radical prostatectomy, award entitlement to SMC (k) for LOU of a creative organ without additional examination or medical opinion. </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Radical prostatectomy results in loss of ejaculatory power and will warrant SMC (k) from the date of the procedure, assuming that the Veteran is already SC for prostate cancer from that date.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Entitlement to SC for ED associated with the radical prostatectomy is a separate factual determination.  For the purposes of determining SMC entitlement following radical prostatectomy, it is irrelevant whether ED also exists at the time the SMC is awarded.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on when SMC is warranted for ED and other sexual dysfunction, see <a href=\"#4b\" target=\"_self\">M21-1, Part V, Subpart iii, 7.4.b</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><h2 class=\"ng-scope\"><br/> </h2><h2 class=\"ng-scope\"><strong><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">4<a id=\"4\" name=\"4\">.</a>  ED</span></span></strong></h2><p class=\"ng-scope\"> <br/>  <br/> </p><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This topic contains information about ED, including</span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4a\" target=\"_self\">ED</a></span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4b\" target=\"_self\">SMC associated with ED or other sexual dysfunction</a></span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4c\" target=\"_self\">ED associated with systemic disease</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4d\" target=\"_self\">scars associated with ED</a>.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">November 15, 2021</span></span></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.7.4.a</span></span><a id=\"4a\" name=\"4a\">.</a> ED</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">ED is evaluated with a noncompensable evaluation under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=4cc8543fd8f53bd5c478fce653e7430d&amp;mc=true&amp;node=se38.1.4_1115b&amp;rgn=div8http://www.ecfr.gov/cgi-bin/text-idx?SID=4cc8543fd8f53bd5c478fce653e7430d&amp;mc=true&amp;node=se38.1.4_1115b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115b, DC 7522</a> without regard to whether penile deformity is present.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on evaluating deformity of the penis under the version of the rating schedule in effect prior to November 14, 2021, see <a articleid=\"554400000115727\" articlename=\"Williams v. Wilkie, Aug 7, 2018, 30 Vet.App. 134 (2018)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000115727/Williams-v-Wilkie-Aug-7-2018-30-VetApp-134-2018\"><em>Williams v. Wilkie</em></a>, 30 Vet.App. 134 (2018).</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>V.iii.7.4.b<a id=\"4b\" name=\"4b\">.</a> Entitlement to SMC Associated With ED </strong></span><span style=\"font-family: arial, helvetica, sans-serif\"><strong>or Other Sexual Dysfunction</strong></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Grant SMC (k) when the evidence shows that SC ED constitutes LOU of a creative organ.  Other diagnoses of sexual dysfunction that may result in LOU include (but are not limited to) loss of libido, loss of sexual drive, or impotence.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When a VA examiner finds that there is ED or other sexual dysfunction, SMC (k) is established even though<span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the Veteran can achieve erection and penetration with the use of medication, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the Veteran had a vasectomy prior to the development of the LOU of a creative organ, as vasectomies may be reversible while LOU is not.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When the evidence, including an examination report or other medical information, shows that a diagnosis of ED or other sexual dysfunction is present but indicates that the Veteran can penetrate and ejaculate <em>without</em> the use of medication, resolve reasonable doubt in the Veteran’s favor and interpret the report to establish that LOU of a creative organ is present and grant entitlement to SMC (k). </span></span></span></span></div></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Exception</em></strong>:  Do <em>not</em> establish SMC(k) based on an examiner’s finding/conclusion that there is ED if</span></span></div></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the examination is insufficient for rating purposes because it is not supported by a valid rationale and/or by the evidence of record (for example if the examiner checks that there is ED but there is no history, examination or other basis for the finding)</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the report is based on the claimant’s report of ED but there is some specific evidence that the claimant’s account of ED lacks credibility, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the preponderance (greater weight) of the evidence proves the contrary.</span></span></div></li></ul><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">entitlement to SMC (k) for LOU of a creative organ, see</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=5d769dc0ed6f3118319651df52a3079c&amp;mc=true&amp;node=se38.1.3_1350&amp;rgn=div8\" target=\"_blank\">38 CFR 3.350(a)(1)</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000177480\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 4, Section A - Special Monthly Compensation (SMC)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177480/M21-1-Part-VIII-Subpart-iv-Chapter-4-Section-A-Special-Monthly-Compensation-SMC\">M21-1, Part VIII, Subpart iv, 4.A.4</a></span></span></li></ul></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">entitlement to SMC (k) associated with radical prostatectomy for prostate cancer, see</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#3d\" target=\"_self\">M21-1, Part V, Subpart iii, 7.3.d</a>, and</span></span></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000177480\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 4, Section A - Special Monthly Compensation (SMC)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177480/M21-1-Part-VIII-Subpart-iv-Chapter-4-Section-A-Special-Monthly-Compensation-SMC\">M21-1, Part VIII, Subpart iv, 4.A.4.c</a></span></span></div></li></ul></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">evaluating ED, see</span></span> <span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=c5cb25770aed6e2e512c2997757a9c9e&amp;mc=true&amp;node=se38.1.4_1115b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115b, DC 7522</a>, and</span></span></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">insufficient examination reports, see <a articleid=\"554400000180517\" articlename=\"M21-1, Part IV, Subpart i, Chapter 3, Section C - Insufficient Examinations\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180517/M21-1-Part-IV-Subpart-i-Chapter-3-Section-C-Insufficient-Examinations\">M21-1, Part IV, Subpart i, 3.C</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">procedures for evaluating evidence, see <a articleid=\"554400000014383\" articlename=\"M21-1, Part V, Subpart ii, Chapter 1, Section A - Principles of Reviewing and Weighing Evidence\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014383/M21-1-Part-V-Subpart-ii-Chapter-1-Section-A-Principles-of-Reviewing-and-Weighing-Evidence\">M21-1, Part V, Subpart ii, 1.A</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-size: 14px\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.7.4.c<a id=\"4c\" name=\"4c\">.</a></span><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> ED Associated With Systemic Disease</span></span></span></span></span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">When evaluating residuals of a systemic disease process such as multiple sclerosis or amyotrophic lateral sclerosis and associated ED, award SC for ED and assign a separate evaluation for the ED when it is otherwise appropriate to separately evaluate residuals. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b><i>Exception</i></b>:  Noncompensable complications of diabetes mellitus must be evaluated with the disease process as provided in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=4cc8543fd8f53bd5c478fce653e7430d&amp;mc=true&amp;node=se38.1.4_1119&amp;rgn=div8\" target=\"_blank\">38 CFR 4.119, DC 7913</a>.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b><i>Reference</i></b>:  For more information on the assignment of a separate evaluation for ED associated with systemic disease processes, see <a articleid=\"554400000180833\" articlename=\"M21-1, Part V, Subpart iii, Chapter 12, Section C - Progressive Neurological Disorders\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180833/M21-1-Part-V-Subpart-iii-Chapter-12-Section-C-Progressive-Neurological-Disorders\">M21-1, Part V, Subpart iii, 12.C</a>.</span></span></div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.7.4.d<a id=\"4d\" name=\"4d\">.</a>  Scars Associated With ED </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Evaluations for ED assigned under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=c5cb25770aed6e2e512c2997757a9c9e&amp;mc=true&amp;node=se38.1.4_1115b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115b, DC 7522</a> account for the functional impairment arising from disease or traumatic injury.  Evaluation under this DC does not preclude a separate evaluation for non-functional impairment, such as painful scarring, under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=39c8a86b5a5a8023a72370f3b7aa987c&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118</a> when otherwise warranted. </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><h2 class=\"ng-scope\"> <br/> </h2><h2 class=\"ng-scope\"><strong><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">5<a id=\"5\" name=\"5\">.</a>  Other Genitourinary Considerations</span></span></strong></h2><p class=\"ng-scope\"> <br/> </p><div class=\"ng-scope\" style=\"margin-left: 1.2in\"> <br/> </div><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This topic contains information about other genitourinary considerations, including</span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#5a\" target=\"_self\">residuals of venereal disease or human immunodeficiency virus (HIV)-related illness</a></span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#5b\" target=\"_self\">kidney donation</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#5c\" target=\"_self\">hydrocele and varicocele</a>.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">November 15, 2021</span></span></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-size: 14px\"><span style=\"font-size: 14px\">V.iii.7.5.a<a id=\"5a\" name=\"5a\">.</a></span></span></span><span style=\"font-size: 14px\"> Residuals of Venereal Disease or HIV-Related Illness</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Do <strong><em>not</em> </strong>consider specific residuals of venereal disease or human immunodeficiency virus (HIV)-related illness to be the result of willful misconduct.</span></span><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Determine SC for residuals of venereal disease or HIV-related illness by the same general principles applicable to resolution of the issue of SC for other diseases.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">willful misconduct and venereal disease, see <a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=1&amp;SID=7c54c98c7be24cd2f7b05eabb45f8a87&amp;ty=HTML&amp;h=L&amp;r=SECTION&amp;n=se38.1.3_1301\">38 CFR 3.301(c)(1)</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">considering claims for SC of human papillomavirus infection (HPV), see <a articleid=\"554400000180511\" articlename=\"M21-1, Part V, Subpart iii, Chapter 8, Section A - Disabilities of the Gynecological System\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180511/M21-1-Part-V-Subpart-iii-Chapter-8-Section-A-Disabilities-of-the-Gynecological-System\">M21-1, Part V, Subpart iii, 8.A.2.f</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">disability or death from use of drugs, see <a articleid=\"554400000177988\" articlename=\"M21-1, Part X, Subpart iv, Chapter 1, Section D  - Disability  or Death from Use of Alcohol, Drugs, or Tobacco Products\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177988/M21-1-Part-X-Subpart-iv-Chapter-1-Section-D-Disability-or-Death-from-Use-of-Alcohol-Drugs-or-Tobacco-Products\">M21-1, Part X, Subpart iv, 1.D</a>.</span></span></span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.7.5.b<a id=\"5b\" name=\"5b\">.</a>  Kidney Donation</span></span></h3><p></p><p></p></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Kidney donation and any expected residual effects thereof are <em>not</em> subject to SC. Kidney donation is considered an elective surgery, and therefore, does not meet the provisions of a disease or injury incurred coincident with service.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> <strong><em>Reference</em></strong>:  For more information about the principles relating to SC, see</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=faf94b4af1bc629e74a43b1bdf68a224&amp;mc=true&amp;node=se38.1.3_1303&amp;rgn=div8\" target=\"_blank\">38 CFR 3.303</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000180481\" articlename=\"M21-1, Part V, Subpart ii, Chapter 2, Section A - Direct Service Connection (SC) and Service Incurrence of an Injury\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180481/M21-1-Part-V-Subpart-ii-Chapter-2-Section-A-Direct-Service-Connection-SC-and-Service-Incurrence-of-an-Injury\">M21-1, Part V, Subpart ii, 2.A</a>.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"display: none\"> </span><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.7.5.c<a id=\"5c\" name=\"5c\">.</a>  Hydrocele and Varicocele </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b><i>Hydrocele</i></b> is a collection of fluid in the scrotum.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b><i>Varicocele</i></b> is a dilatation of the veins along the cord that receives blood from the testicles.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">These conditions may be associated with a decrease in fertility and, in rare instances, may be associated with infertility.  In instances where there is a clinical finding of infertility which is linked to the hydrocele or varicocele, entitlement to SMC is warranted.<span style=\"display: none\"> </span></span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><p style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000014523\" articlename=\"M21-1, Part V, Subpart iii, Chapter 6 - Digestive Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014523/M21-1-Part-V-Subpart-iii-Chapter-6-Digestive-Disabilities\">&lt;-- Previous Section</a> <a articleid=\"554400000180511\" articlename=\"M21-1, Part V, Subpart iii, Chapter 8, Section A - Disabilities of the Gynecological System\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180511/M21-1-Part-V-Subpart-iii-Chapter-8-Section-A-Disabilities-of-the-Gynecological-System\">Next Section --&gt;</a></span></span></p></div><p class=\"ng-scope\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#top\" target=\"_self\"><span style=\"font-size: 11px\">To Top</span></a></span></p><p class=\"ng-scope\"></p></div>\n</div>",
  "external_links": [
    "http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=222ee19dbafbd3e428f19ca334315408&mc=true&r=SECTION&n=se38.1.4_1115b",
    "http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=81b516116b4e110561af986fced965c2&mc=true&r=SECTION&n=se38.1.4_1115a",
    "http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=81b516116b4e110561af986fced965c2&mc=true&r=SECTION&n=se38.1.4_1115b",
    "http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=1&SID=7c54c98c7be24cd2f7b05eabb45f8a87&ty=HTML&h=L&r=SECTION&n=se38.1.3_1301",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=35ef52f6227f4eabafb59020ae1d9dbf&mc=true&node=se38.1.4_1115b&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=4cc8543fd8f53bd5c478fce653e7430d&mc=true&node=se38.1.4_1115b&rgn=div8http://www.ecfr.gov/cgi-bin/text-idx?SID=4cc8543fd8f53bd5c478fce653e7430d&mc=true&node=se38.1.4_1115b&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=4cc8543fd8f53bd5c478fce653e7430d&mc=true&node=se38.1.4_1119&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=54c96c965aea2c1b50e0224171bc3e6e&mc=true&node=se38.1.4_1115&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=54c96c965aea2c1b50e0224171bc3e6e&mc=true&node=se38.1.4_1115a&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=5d769dc0ed6f3118319651df52a3079c&mc=true&node=se38.1.3_1350&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=6c3a70b2672bd39e52a4f1bf53f43098&mc=true&node=se38.1.4_1115b&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=72261cd9b25e4292a9f5a93cf52f6aa3&mc=true&node=se38.1.4_1115b&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=c5cb25770aed6e2e512c2997757a9c9e&mc=true&node=se38.1.4_1115b&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=f0927e0449515a9d9a73c8c631159550&mc=true&node=se38.1.4_1115a&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=f93b52b98906ac6c4e0978043b1b051a&mc=true&node=se38.1.3_1400&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=faf94b4af1bc629e74a43b1bdf68a224&mc=true&node=se38.1.3_1303&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=39c8a86b5a5a8023a72370f3b7aa987c&mc=true&node=se38.1.4_1118&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=3ef32e0ff149cd613c9936c7ba66cbad&mc=true&node=se38.1.4_1115a&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=ca6780f87ddf9e811ae2485e04ad8d0a&mc=true&node=se38.1.4_1115a&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=fc5847cf90d70d828fac9668b29a7975&mc=true&node=se38.1.4_1115b&rgn=div8",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR63da83ba671b92b/section-3.105#p-3.105(e)",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.14",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR8198d98a7a48906/section-4.115",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR8198d98a7a48906/section-4.115#p-4.115(b)",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR8198d98a7a48906/section-4.115a",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR8198d98a7a48906/section-4.115b"
  ],
  "scraped_at": "2025-06-16T22:45:07.512056",
  "next_section": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180511/M21-1-Part-V-Subpart-iii-Chapter-8-Section-A-Disabilities-of-the-Gynecological-System"
}